AMN Healthcare Services (AMN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 2, 2025, with virtual attendance available for shareholders.
Shareholders are invited to vote on key proposals, including director elections, executive compensation, auditor ratification, an equity plan, and a shareholder proposal.
Voting matters and shareholder proposals
Nine directors are nominated for election, with the board recommending a vote for each.
Advisory vote on executive compensation is recommended for approval by the board.
Ratification of KPMG LLP as the independent auditor for fiscal year ending December 31, 2025, is recommended.
Approval of the 2025 Equity Plan is recommended by the board.
A shareholder proposal to improve special shareholder meeting procedures is recommended against by the board.
Board of directors and corporate governance
Director nominees include Jorge A. Caballero, Mark G. Foletta, Teri G. Fontenot, Cary S. Grace, R. Jeffrey Harris, James H. Hinton, Celia P. Huber, Daphne E. Jones, and Sylvia D. Trent-Adams.
Latest events from AMN Healthcare Services
- Proxy seeks approval of director slate, executive pay, auditor, equity plan, and rejects board chair proposal.AMN
Proxy Filing18 Mar 2026 - Virtual annual meeting set for May 1, 2026, with online voting available until April 30.AMN
Proxy Filing18 Mar 2026 - Q4 revenue up 2% year-over-year; Q1 2026 outlook projects 78–80% revenue growth.AMN
Q4 202520 Feb 2026 - Revenue and earnings declined sharply, but strong cash flow enabled significant debt reduction.AMN
Q2 20241 Feb 2026 - Q3 revenue beat expectations but fell 19% year-over-year; margin and demand pressures persist.AMN
Q3 202415 Jan 2026 - Q4 beat expectations, but a $222 million impairment led to a net loss and lower 2024 revenue.AMN
Q4 202411 Dec 2025 - Restructuring, tech innovation, and governance changes mark a pivotal year, with key votes ahead.AMN
Proxy Filing1 Dec 2025 - Q2 2025 revenue near guidance highs, but $116.2M net loss from $128M impairments.AMN
Q2 202523 Nov 2025 - Q1 2025 revenue declined 16% year-over-year, but cash flow and tech adoption remain strong.AMN
Q1 202521 Nov 2025